New combination of drugs works together to reduce lung tumors in mice

New study shows FDA-approved trametinib and entinostat can be given in tandem to produce fewer tumors in mice with LKB1-mutated NSCLC.

The findings may lead to clinical trials to test the new regimen in humans.

The discovery could have potential applications in lymphoma, melanoma, and pancreatic cancer.

The work was supported by the National Institutes of Health (R35CA220538, P01CA120964, K22CA251636, 5T32CA009370, 5F32CA206400, CCSG P30CA014195, and CCSG P30CA23100), Leona M. and Harry B. Helmsley Charitable Trust (#2012-PG-MED002), American Cancer Society (PF-15-037-01-DMC), and Chapman Foundation. Story Source: Journal Reference: Cite This Page:.